<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>77_Guillain-Barre Syndrome and Other Immune-mediat... - Marrow Medicine</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <style>
        .medical-quiz {
            font-family: Segoe UI, Tahoma, Geneva, Verdana, sans-serif;
        }
        
        .question-card {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
        }
        
        .option-card {
            transition: all 0.3s ease;
            cursor: pointer;
            border: 2px solid transparent;
        }
        
        .option-card:hover {
            border-color: #3b82f6;
            transform: translateY(-2px);
        }
        
        .option-card.selected {
            background: #3b82f6;
            color: white;
            border-color: #1d4ed8;
        }
        
        .option-card.correct {
            background: #10b981;
            color: white;
            border-color: #059669;
        }
        
        .option-card.incorrect {
            background: #ef4444;
            color: white;
            border-color: #dc2626;
        }
        
        .progress-bar {
            background: linear-gradient(to right, #10b981, #059669);
            transition: width 0.3s;
        }
        
        .medical-image {
            max-width: 100%;
            max-height: 400px;
            height: auto;
            border-radius: 12px;
            margin: 20px auto;
            display: block;
        }
        
        .hidden {
            display: none !important;
        }

        .explanation-content {
            font-family: Segoe UI, Tahoma, Geneva, Verdana, sans-serif;
            font-size: 1.05rem;
            line-height: 1.7;
            color: #374151;
            text-align: left;
        }
        
        .explanation-content p {
            margin-bottom: 1rem;
            text-align: justify;
        }
        
        .explanation-content strong, .explanation-content b {
            font-weight: 600;
            color: #1f2937;
        }
        
        .explanation-content img {
            max-width: 100%;
            height: auto;
            margin: 1.5rem auto;
            display: block;
            border-radius: 8px;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
        }
    </style>
</head>

<body class="bg-gradient-to-br from-blue-50 to-indigo-100 min-h-screen medical-quiz">
    <header class="bg-white shadow-xl p-6">
        <div class="container mx-auto flex justify-between items-center">
            <div>
                <h1 class="text-3xl font-bold text-gray-800">77_Guillain-Barre Syndrome and Other Immune-mediat...</h1>
                <p class="text-gray-600 mt-2">Marrow ‚Ä¢ Medicine ‚Ä¢ Interactive Learning</p>
            </div>
            <div class="flex gap-2">
                <button class="bg-gray-500 text-white px-3 py-2 text-sm rounded-lg hover:bg-gray-600 transition" 
                        onclick="window.location.href='marrow_medicine.html'">
                    ‚Üê Topics
                </button>
                <button class="bg-purple-500 text-white px-3 py-2 text-sm rounded-lg hover:bg-purple-600 transition" 
                        onclick="window.location.href='marrow.html'">
                    üìö Marrow
                </button>
                <button class="bg-blue-500 text-white px-3 py-2 text-sm rounded-lg hover:bg-blue-600 transition" 
                        onclick="window.location.href='index.html'">
                    üè† Home
                </button>
            </div>
        </div>
    </header>

    <!-- Statistics Bar (Hidden in Test Mode) -->
    <div class="bg-white shadow-lg p-4" id="stats-bar">
        <div class="container mx-auto flex justify-center gap-8">
            <div class="text-center">
                <div class="text-2xl font-bold text-green-600" id="correct-stats">0</div>
                <div class="text-sm text-gray-600">Correct</div>
            </div>
            <div class="text-center">
                <div class="text-2xl font-bold text-red-600" id="incorrect-stats">0</div>
                <div class="text-sm text-gray-600">Incorrect</div>
            </div>
            <div class="text-center">
                <div class="text-2xl font-bold text-blue-600" id="accuracy-stats">0%</div>
                <div class="text-sm text-gray-600">Accuracy</div>
            </div>
            <div class="text-center">
                <div class="text-2xl font-bold text-purple-600" id="progress-stats">0/21</div>
                <div class="text-sm text-gray-600">Progress</div>
            </div>
        </div>
    </div>

    <!-- Quiz Section -->
    <section class="container mx-auto p-6" id="quiz-section">
        <div class="bg-white rounded-2xl shadow-xl p-8">
            <!-- Progress Bar -->
            <div class="w-full bg-gray-200 rounded-full h-4 mb-8">
                <div class="progress-bar h-4 rounded-full" id="progress-bar"></div>
            </div>

            <div class="flex justify-between items-center mb-8">
                <h2 class="text-2xl font-bold text-blue-700" id="question-number">Question 1 of 21</h2>
                <div class="text-sm text-gray-600" id="question-status">Click an option to answer</div>
            </div>

            <!-- Question Text -->
            <div class="mb-10">
                <div class="question-card text-white p-8 rounded-2xl mb-8" id="question-text"></div>
                
                <!-- Question Image -->
                <div class="text-center mb-8" id="question-images"></div>
                
                <!-- Options -->
                <div class="space-y-4" id="options"></div>
            </div>

            <!-- Answer Feedback Section (Normal Mode Only) -->
            <div class="hidden mb-8 p-6 rounded-2xl" id="feedback-section">
                <div class="text-center mb-4">
                    <div class="text-6xl mb-2" id="feedback-icon"></div>
                    <div class="text-2xl font-bold mb-2" id="feedback-message">Correct!</div>
                </div>
                
                <div class="grid md:grid-cols-2 gap-4 mb-4">
                    <div class="bg-white p-4 rounded-xl border">
                        <strong>Your Answer:</strong><br>
                        <span id="user-answer-display"></span>
                    </div>
                    <div class="bg-white p-4 rounded-xl border">
                        <strong>Correct Answer:</strong><br>
                        <span class="text-green-600" id="correct-answer-display"></span>
                    </div>
                </div>
                
                <div class="bg-blue-50 p-6 rounded-xl" id="explanation-section">
                    <strong class="text-lg text-blue-800">Explanation:</strong>
                    <div id="explanation-content" class="mt-3 explanation-content"></div>
                </div>
            </div>

            <!-- Navigation -->
            <div class="flex justify-between gap-4">
                <button class="bg-gray-400 text-white px-6 py-3 rounded-xl hover:bg-gray-500 transition" 
                        onclick="window.location.href='marrow_medicine.html'">
                    Back to Topics
                </button>
                
                <div class="flex gap-4">
                    <button class="bg-gray-400 text-white px-6 py-3 rounded-xl disabled" id="prev-btn">
                        Previous
                    </button>
                    <button class="bg-blue-500 text-white px-6 py-3 rounded-xl hidden" id="next-btn">
                        Next
                    </button>
                    <button class="bg-green-600 text-white px-6 py-3 rounded-xl font-bold hidden" id="finish-btn">
                        Finish Quiz
                    </button>
                </div>
            </div>
        </div>
    </section>

    <!-- Test Mode Final Results -->
    <section class="container mx-auto p-6 hidden" id="test-results">
        <div class="bg-white rounded-2xl shadow-xl p-8">
            <div class="text-center mb-8">
                <h2 class="text-4xl font-bold mb-4 text-blue-700">Test Complete! üéâ</h2>
                <div class="text-6xl mb-4" id="test-grade-icon">üéØ</div>
            </div>
            
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="bg-green-100 p-6 rounded-2xl text-center">
                    <div class="text-4xl font-bold text-green-600" id="test-final-correct">0</div>
                    <div class="font-semibold text-green-700">Correct Answers</div>
                </div>
                <div class="bg-red-100 p-6 rounded-2xl text-center">
                    <div class="text-4xl font-bold text-red-600" id="test-final-incorrect">0</div>
                    <div class="font-semibold text-red-700">Incorrect Answers</div>
                </div>
                <div class="bg-blue-100 p-6 rounded-2xl text-center">
                    <div class="text-4xl font-bold text-blue-600" id="test-final-accuracy">0%</div>
                    <div class="font-semibold text-blue-700">Final Accuracy</div>
                </div>
            </div>

            <!-- Detailed Review -->
            <div class="mb-8">
                <h3 class="text-2xl font-bold text-gray-800 mb-4">üìã Detailed Review</h3>
                <div id="test-review-details" class="space-y-4"></div>
            </div>
            
            <div class="flex justify-center gap-4">
                <button class="bg-purple-600 text-white px-8 py-3 rounded-xl font-bold hover:bg-purple-700 transition" 
                        onclick="window.location.href='marrow_medicine.html'">
                    Back to Topics
                </button>
                <button class="bg-blue-600 text-white px-8 py-3 rounded-xl font-bold hover:bg-blue-700 transition" 
                        onclick="window.location.reload()">
                    Retake Quiz
                </button>
            </div>
        </div>
    </section>

    <!-- Normal Mode Final Results -->
    <section class="container mx-auto p-6 hidden" id="final-results">
        <div class="bg-white rounded-2xl shadow-xl p-8">
            <div class="text-center mb-8">
                <h2 class="text-4xl font-bold mb-4 text-blue-700">Quiz Complete! üéâ</h2>
                <div class="text-6xl mb-4" id="final-grade-icon">üéØ</div>
            </div>
            
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="bg-green-100 p-6 rounded-2xl text-center">
                    <div class="text-4xl font-bold text-green-600" id="final-correct">0</div>
                    <div class="font-semibold text-green-700">Correct Answers</div>
                </div>
                <div class="bg-red-100 p-6 rounded-2xl text-center">
                    <div class="text-4xl font-bold text-red-600" id="final-incorrect">0</div>
                    <div class="font-semibold text-red-700">Incorrect Answers</div>
                </div>
                <div class="bg-blue-100 p-6 rounded-2xl text-center">
                    <div class="text-4xl font-bold text-blue-600" id="final-accuracy">0%</div>
                    <div class="font-semibold text-blue-700">Final Accuracy</div>
                </div>
            </div>
            
            <div class="flex justify-center gap-4">
                <button class="bg-purple-600 text-white px-8 py-3 rounded-xl font-bold hover:bg-purple-700 transition" 
                        onclick="window.location.href='marrow_medicine.html'">
                    Back to Topics
                </button>
                <button class="bg-blue-600 text-white px-8 py-3 rounded-xl font-bold hover:bg-blue-700 transition" 
                        onclick="window.location.reload()">
                    Retake Quiz
                </button>
            </div>
        </div>
    </section>

    <script>
        const questions = [
  {
    "id": 1418,
    "text": "Q1. Which of the following is the most common antecedent infectious cause of Guillain-Barre syndrome?",
    "options": [
      {
        "label": "A",
        "text": "Cytomegalovirus",
        "correct": false
      },
      {
        "label": "B",
        "text": "Mycoplasma pneumoniae",
        "correct": false
      },
      {
        "label": "C",
        "text": "Campylobacter jejuni",
        "correct": true
      },
      {
        "label": "D",
        "text": "Epstein Barr virus",
        "correct": false
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">Campylobacter jejuni is one of the most common risk factors for GBS. Infections that may trigger GBS are: * Campylobacter jejuni * Cytomegalovirus (CMV) ¬¢ Epstein Barr virus * Mycoplasma * Varicella zoster virus * Human immunodeficiency virus (HIV), dengue, or influenza, Zika, hepatitis Less commonly vaccinations, surgical procedures, and trauma have been reported to trigger the development of GBS.</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "C. Campylobacter jejuni"
  },
  {
    "id": 1419,
    "text": "Q2. Which of the following autoantibody isotype is involved in the pathogenesis of Guillian-Barre syndrome?",
    "options": [
      {
        "label": "A",
        "text": "IgA",
        "correct": false
      },
      {
        "label": "B",
        "text": "IgG",
        "correct": true
      },
      {
        "label": "C",
        "text": "IgM",
        "correct": false
      },
      {
        "label": "D",
        "text": "IgE",
        "correct": false
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">IgG isotype of autoantibody is involved in the pathogenesis of GBS. IgM isotype autoantibodies are known to play a role in some types of chronic immune neuropathies.</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "B. IgG"
  },
  {
    "id": 1420,
    "text": "Q3. In Guillain-Barre syndrome due to antecedent infection with Campylobacter jejuni, the autoantibodies are most commonly directed against which of the following?",
    "options": [
      {
        "label": "A",
        "text": "GM1",
        "correct": true
      },
      {
        "label": "B",
        "text": "GDia",
        "correct": false
      },
      {
        "label": "C",
        "text": "GDib",
        "correct": false
      },
      {
        "label": "D",
        "text": "GalNac-GDia",
        "correct": false
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">Autoantibodies in GBS due to Campylobacter jejuni infection are directed most commonly against GM1 gangliosidase.</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "A. GM1"
  },
  {
    "id": 1421,
    "text": "Q4. Which of the following is the most common type of Guillian-Barre syndrome? 1142",
    "options": [
      {
        "label": "A",
        "text": "Acute motor axonal neuropathy",
        "correct": false
      },
      {
        "label": "B",
        "text": "Acute inflammatory demyelinating polyneuropathy",
        "correct": true
      },
      {
        "label": "C",
        "text": "Acute motor sensory axonal neuropathy",
        "correct": false
      },
      {
        "label": "D",
        "text": "Miller Fisher syndrome",
        "correct": false
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">Acute inflammatory demyelinating polyneuropathy (AIDP) is the most common type of GBS. There are several types of Guillain-Barre syndrome, which are recognized by electrodiagnostic studies and pathological distinctions. These include: A. Demyelinating * Acute inflammatory demyelinating polyneuropathy (AIDP) - most common B. Axonal ¬¢ Acute motor axonal neuropathy (AMAN) ¬´ Acute motor‚Äîsensory axonal neuropathy (AMSAN) C. Regional GBS syndromes * Miller‚ÄîFisher syndrome (MFS) 1149 * Pure sensory forms * Ophthalmoplegia with anti-GQib antibodies as part of severe motor-sensory GBS * GBS with severe bulbar and facial paralysis * Acute pandysautonomia</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "B. Acute inflammatory demyelinating polyneuropathy"
  },
  {
    "id": 1422,
    "text": "Q5. Which type of Guillain-Barre syndrome most commonly affects patients in the pediatric age group?",
    "options": [
      {
        "label": "A",
        "text": "Acute motor axonal neuropathy",
        "correct": true
      },
      {
        "label": "B",
        "text": "Acute inflammatory demyelinating polyneuropathy",
        "correct": false
      },
      {
        "label": "C",
        "text": "Acute motor sensory axonal neuropathy",
        "correct": false
      },
      {
        "label": "D",
        "text": "Miller Fisher syndrome",
        "correct": false
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">The acute motor axonal neuropathy (AMAN) subtype of Guillain-Barre syndrome (GBS) is more common in pediatric age groups. Acute inflammatory demyeli | Adults nating polyneuropathy (AIDP) Acute motor axonal neuropat | ChildrenYoung adu hy (AMAN) Its Acute motor-sensory axonal Mostly adults neuropathy (AMSAN) Miller‚ÄîFisher syndrome AdultsChildren</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "A. Acute motor axonal neuropathy"
  },
  {
    "id": 1423,
    "text": "Q6. Acute inflammatory demyelinating polyneuropathy differs from acute motor axonal neuropathy, in that, in the latter, the complement deposition along with IgG antibodies occurs at:",
    "options": [
      {
        "label": "A",
        "text": "Nodes of Ranvier",
        "correct": true
      },
      {
        "label": "B",
        "text": "Neuromuscular junction",
        "correct": false
      },
      {
        "label": "C",
        "text": "Oligodendrocytes",
        "correct": false
      },
      {
        "label": "D",
        "text": "Schwann cells",
        "correct": false
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">In AMAN, the complement along with IgG is deposited at the nodes of Ranvier of large motor axons. In AIDP, complement deposits along the outer surface of the Schwann cell.</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "A. Nodes of Ranvier"
  },
  {
    "id": 1424,
    "text": "Q7. Which of the following features would you not expect to see in a patient with Guillian-Barre syndrome?",
    "options": [
      {
        "label": "A",
        "text": "Absent reflexes in lower limb",
        "correct": false
      },
      {
        "label": "B",
        "text": "Ascending paralysis",
        "correct": false
      },
      {
        "label": "C",
        "text": "Early bladder dysfunction",
        "correct": true
      },
      {
        "label": "D",
        "text": "Bulbar paralysis",
        "correct": false
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">Bladder dysfunction is not usually severe and does not appear early in the course of Guillain-Barre Syndrome(GBS). If bladder dysfunction is a prominent feature and comes early in the course, diagnostic possibilities other than GBS should be considered. GBS is an acute demyelinating polyradiculoneuropathy. It is an autoimmune disorder triggered by infections like: * Campylobacter jejuni * Cytomegalovirus (CMV) ¬¢ Epstein Barr virus * Mycoplasma * Varicella zoster virus 1150 * Human immunodeficiency virus (HIV), dengue, or influenza It manifests as a rapidly evolving areflexic motor paralysis, with or without sensory disturbance. The usual pattern is ascending paralysis. Proximal and distal muscles are equally involved. The lower cranial nerves are frequently affected, causing bulbar weakness.</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "C. Early bladder dysfunction"
  },
  {
    "id": 1425,
    "text": "Q8. 1143 Which of the following sensory deficits is severely affected in a patient with Guillain-Barre syndrome?",
    "options": [
      {
        "label": "A",
        "text": "Pain",
        "correct": false
      },
      {
        "label": "B",
        "text": "Temperature",
        "correct": false
      },
      {
        "label": "C",
        "text": "Proprioception",
        "correct": true
      },
      {
        "label": "D",
        "text": "Touch",
        "correct": false
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">Loss of proprioception is severe in Guillain-Barre syndrome (GBS). GBS affects the large sensory fibers, leading to attenuation or loss of deep tendon reflexes and loss of proprioception. Cutaneous sensory deficits (e. g. , loss of pain and temperature sensation) are usually relatively mild.</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "C. Proprioception"
  },
  {
    "id": 1426,
    "text": "Q9. patient presents with complaints of lower extremity weakness. He initially noticed difficulty climbing the stairs and now he is unable to stand. He gives a history of bloody diarrhea a few weeks ago. Which of the following parameters are expected to be elevated in the CSF of this patient?",
    "options": [
      {
        "label": "A",
        "text": "Lymphocytes",
        "correct": false
      },
      {
        "label": "B",
        "text": "Neutrophils",
        "correct": false
      },
      {
        "label": "C",
        "text": "Opening pressure",
        "correct": false
      },
      {
        "label": "D",
        "text": "Proteins",
        "correct": true
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">The given scenario is suggestive of Guillain-Barre syndrome (GBS). Protein levels are elevated (100-1000mg/dl) in the CSF of a patient with this condition. The CSF cell counts are usually normal. Albuminocytologic dissociation, which is an elevation in CSF protein without an elevation in white blood cells, is characteristic in GBS. Causes of albuminocytologic dissociation are: * Guillain-Barre Syndrome * Spinal cord tumours</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "D. Proteins"
  },
  {
    "id": 1427,
    "text": "Q10. Which of the following conditions does not present with autonomic dysfunction?",
    "options": [
      {
        "label": "A",
        "text": "Amyloidosis",
        "correct": false
      },
      {
        "label": "B",
        "text": "Guillain-Barr√© syndrome",
        "correct": false
      },
      {
        "label": "C",
        "text": "Botulism",
        "correct": false
      },
      {
        "label": "D",
        "text": "Subclavian steal syndrome",
        "correct": true
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">Subclavian steal syndrome does not present with autonomic dysfunction. Option A: Polyneuropathy is seen in sporadic and familial amyloidosis. In some cases, autonomic insufficiency presents before distal painful polyneuropathy accompanied by sensory loss Option B: Guillain-Barr√© syndrome is associated with autonomic instability. This can present with BP fluctuations, arrhythmias, and GI disturbances. Option C: Botulinum toxin binds presynaptically to cholinergic nerve terminals. After uptake into the cytoplasm, it blocks ACh release. Thus, patients with botulism present with motor paralysis and autonomic disturbances.</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "D. Subclavian steal syndrome"
  },
  {
    "id": 1428,
    "text": "Q11. 23-year-old patient presents with rapidly progressing symmetric ascending paralysis since 2 days. Nerve conduction studies are consistent with demyelination. He is found to have an elevated protein level in his CSF. Which of the following autonomic disturbance is likely to be seen in this patient?",
    "options": [
      {
        "label": "A",
        "text": "Postural hypotension",
        "correct": true
      },
      {
        "label": "B",
        "text": "Urinary incontinence 1144",
        "correct": false
      },
      {
        "label": "C",
        "text": "Diarrhea",
        "correct": false
      },
      {
        "label": "D",
        "text": "Increased sweating",
        "correct": false
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">1151 The given scenario is suggestive of Guillian-Barre syndrome (GBS). Postural hypotension is a common autonomic disturbance seen in this condition. Autonomic involvement is common and may occur even in patients whose GBS is otherwise mild. The usual autonomic manifestations are: * Loss of vasomotor control with wide fluctuation in blood pressure, postural hypotension * Cardiac dysrhythmias</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "A. Postural hypotension"
  },
  {
    "id": 1429,
    "text": "Q12. The triad of Miller-Fisher syndrome includes all of the following, except:",
    "options": [
      {
        "label": "A",
        "text": "Ataxia",
        "correct": false
      },
      {
        "label": "B",
        "text": "Weakness",
        "correct": true
      },
      {
        "label": "C",
        "text": "Areflexia",
        "correct": false
      },
      {
        "label": "D",
        "text": "Ophthalmoplegia",
        "correct": false
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">Weakness is not seen in the triad of Miller-Fisher syndrome (MFS). Miller Fisher syndrome is a variant of Guillain-Barr√© syndrome(GBS). Like Guillain-Barr√© syndrome, symptoms may be preceded by a viral illness. It classically presents as a triad of: * Ataxia * Areflexia * Ophthalmoplegia The condition is usually not associated with weakness, and even if present, is very mild. It is strongly associated with antibodies to the ganglioside GQib. The prognosis in Miller Fisher syndrome is usually good with recovery beginning within 2 to 4 weeks of the symptom onset, and completing by 6 months. Some individuals are left with residual deficits. Relapses are rare. Treatment for Miller Fisher syndrome is identical to treatment for Guillain-Barr√© syndrome: intravenous immunoglobulin (IVIg) or plasmapheresis and supportive care.</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "B. Weakness"
  },
  {
    "id": 1430,
    "text": "Q13. patient presented to the ER with tingling, numbness, and weakness in all four limbs. She says that the weakness started in the lower limbs and progressed to the upper limbs within a day. History is significant for a recent COVID-19 infection and surgery for cervical spondylosis and disc herniation 3 years ago. CT brain was normal and an MRI of the lumbar spine showed foraminal narrowing at L2-L3. CSF analysis showed increased protein levels. Which of the following is recommended for the initial therapy of this patient?",
    "options": [
      {
        "label": "A",
        "text": "Intrathecal steroids",
        "correct": false
      },
      {
        "label": "B",
        "text": "Remdesivir",
        "correct": false
      },
      {
        "label": "C",
        "text": "IV Immunoglobulin",
        "correct": true
      },
      {
        "label": "D",
        "text": "Plasmapheresis",
        "correct": false
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">The given scenario is suggestive of Guillain-Barre syndrome(GBS) probably as a result of COVID-19. IV Immunoglobulin is the recommended initial therapy for patients with GBS. High-dose intravenous immune globulin (IVIg) and plasmapheresis are both equally effective in GBS and can be used as the initial therapy. However, IVIg is often the initial therapy chosen because of its ease of administration and good safety record. It is administered as five daily infusions for a total dose of 2 g/kg body weight. Glucocorticoids have not been found to be effective in GBS.</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "C. IV Immunoglobulin"
  },
  {
    "id": 1431,
    "text": "Q14. In a patient with Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy is suspected when",
    "options": [
      {
        "label": "A",
        "text": "GBS deteriorates &amp;gt;5 weeks after onset or relapses at least three times",
        "correct": false
      },
      {
        "label": "B",
        "text": "GBS deteriorates &amp;gt;5 weeks after onset or relapses at least two times",
        "correct": false
      },
      {
        "label": "C",
        "text": "GBS deteriorates &amp;gt;9 weeks after onset or relapses at least three times",
        "correct": true
      },
      {
        "label": "D",
        "text": "GBS deteriorates &amp;gt;8 weeks after onset or relapses at least two times",
        "correct": false
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">Chronic inflammatory demyelinating polyneuropathy (CIDP) should be suspected when GBS deteriorates &amp;gt; 9 weeks after onset or relapses at least three times. 1152 Onset is usually gradual over a few months or longer, but in a few cases, the initial attack is indistinguishable from that of GBS. CIDP is distinguished from GBS by its chronic course. In other respects, this neuropathy shares many features with the common demyelinating form of GBS, including elevated CSF protein levels and the electrodiagnostic studies findings of acquired demyelination.</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "C. GBS deteriorates &amp;gt;9 weeks after onset or relapses at least three times"
  },
  {
    "id": 1432,
    "text": "Q15. 1145 Which of the following conditions are not associated with chronic inflammatory demyelinating polyneuropathy?",
    "options": [
      {
        "label": "A",
        "text": "Diabetic mellitus",
        "correct": false
      },
      {
        "label": "B",
        "text": "Systemic lupus erythematosus",
        "correct": false
      },
      {
        "label": "C",
        "text": "Lymphoma",
        "correct": false
      },
      {
        "label": "D",
        "text": "Hepatitis A infection",
        "correct": true
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">Hepatitis A infection is not associated with CIDP. Diseases associated with CIDP are: * Hepatitis B * Hepatitis C * Lymphoma * HIV * Diabetic mellitus * Systemic lupus erythematosus (SLE) * Pregnancy * Paraneoplastic syndrome * Inflammatory bowel disease * Amyloidosis</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "D. Hepatitis A infection"
  },
  {
    "id": 1433,
    "text": "Q16. All are true about chronic inflammatory demyelinating polyneuropathy, except:",
    "options": [
      {
        "label": "A",
        "text": "Symptoms present for &amp;gt; 8 weeks duration",
        "correct": false
      },
      {
        "label": "B",
        "text": "Relapse at least 3 times in a patient with Guillain-Barr√© syndrome",
        "correct": false
      },
      {
        "label": "C",
        "text": "Symmetrical weakness",
        "correct": false
      },
      {
        "label": "D",
        "text": "Small nerve fibers are affected more than large fibers",
        "correct": true
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">Large nerve fibers are affected more than small fibers in CIDP. Difference between CIDP and Guillain-barr√© syndrome(GBS): Duration &lt;4 we | &gt;8 weeks eks Motor symptoms Affect | Affected ed Sensory symptoms Mild | More significantLargefiber &gt; small fiber Autonomic nervous syst | Affect | Rare em ed Antecedent event Prese | Rare nt 1153 t Steroid Noro | 2nd line of treatment le</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "D. Small nerve fibers are affected more than large fibers"
  },
  {
    "id": 1434,
    "text": "Q17. patient with chronic inflammatory demyelinating polyneuropathy is undergoing nerve conduction study. Which of the following findings is least likely to be seen in this patient?",
    "options": [
      {
        "label": "A",
        "text": "Low amplitude",
        "correct": true
      },
      {
        "label": "B",
        "text": "Decreased conduction velocity",
        "correct": false
      },
      {
        "label": "C",
        "text": "Increased distal latency",
        "correct": false
      },
      {
        "label": "D",
        "text": "Conduction block",
        "correct": false
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">In CIDP, the amplitude is normal since the axons are intact. Nerve conduction study (NCS) in axonal injury and demyelinating diseases: Distal latency Prolonged Conduction veloci | Normal Slow ty Temporal dispersi | Absent Present on H wave Normal or abs_ | Prolonged or abse ent nt F wave Normal or abs_ | Prolonged or abse ent nt</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "A. Low amplitude"
  },
  {
    "id": 1435,
    "text": "Q18. In which of the following situations is nerve biopsy not indicated in patients with chronic inflammatory demyelinating polyneuropathy?",
    "options": [
      {
        "label": "A",
        "text": "When the diagnosis not clear",
        "correct": false
      },
      {
        "label": "B",
        "text": "When other causes of polyneuropathy cannot be ruled out",
        "correct": false
      },
      {
        "label": "C",
        "text": "When electromyography shows axonal involvement",
        "correct": false
      },
      {
        "label": "D",
        "text": "When there is no clinical or electrophysiological evidence of nerve functionality 1146",
        "correct": true
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">Nerve biopsy should not be done if there is no clinical or electrophysiological evidence of nerve functionality of that nerve in CIDP patients. This is because completely degenerated nerves usually convey limited information. In CIDP, nerve biopsy is indicated when: * Diagnosis is not clear * Other causes of polyneuropathy cannot be ruled out * Electromyography (EMG) shows axonal involvement</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "D. When there is no clinical or electrophysiological evidence of nerve functionality 1146"
  },
  {
    "id": 1436,
    "text": "Q19. All of the following can be used for the treatment of a patient with chronic inflammatory demyelinating polyneuropathy, except:",
    "options": [
      {
        "label": "A",
        "text": "IV Immunoglobulin",
        "correct": false
      },
      {
        "label": "B",
        "text": "Plasmapheresis",
        "correct": false
      },
      {
        "label": "C",
        "text": "NSAIDs",
        "correct": true
      },
      {
        "label": "D",
        "text": "Glucocorticoids",
        "correct": false
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">NSAIDs are not used in the treatment of CIDP. 1154 The treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) includes high-dose IV immunoglobulin, plasmapheresis, and glucocorticoids. Initial therapy is usually with IV immunoglobulin. If all the first-line agents fail, immunosuppressants are attempted either alone or as an adjunctive treatment.</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "C. NSAIDs"
  },
  {
    "id": 1437,
    "text": "Q20. 63-year-old man presented with complaints of fatiguability and chronic back pain. On evaluation, he was found to have anemia and hypercalcemia. The X-ray of his skull is given below. Which of the following statements is true with regard to neuropathy seen in this condition?",
    "options": [
      {
        "label": "A",
        "text": "bald , L Polyneuropathy is seen in 50% of patients presenting with osteoporotic bone lesions",
        "correct": false
      },
      {
        "label": "B",
        "text": "Polyneuropathy is seen in 5% of patients presenting with osteosclerotic features",
        "correct": false
      },
      {
        "label": "C",
        "text": "The pattern is sensorimotor",
        "correct": true
      },
      {
        "label": "D",
        "text": "Treatment may reverse severe neuropathy",
        "correct": false
      }
    ],
    "imageData": {
      "data": "UklGRnI1AABXRUJQVlA4IGY1AAAwbAKdASogA1kCPm00k0asKK0mqhjqsaANiWktnQ6PgGnkvgJgQEPP75rDLsrhJvqp/Sj//oGmnWgPXZuf3B/+I/+z0TfG/9v/9f8X0B/JP4f/x5+exPv5yw8wn/76e/g//dr4YceDQOk074cde7C7u20F3dtoLu7Z+OEssNupGpa2Vir9QYBP+QVSciBUreYL73OTVAK/Qh1RjoWN7e/j/7x7BjPW0/YEsaW2JY0tsSxpbYljS2xLFyUfUUVPzrs1swLwngGEieG9HX2vOf4qE2VXd5liWKp//7o/Pym3IKhwCEvdmlBWH2VgfKV18M3bCP1BI9aMIBzDKeIRG+bLiT5idG/7GV55D9g5hGB2mxUszmD9ArDYqRjIRTutbMC1k5cGtavroe+XTHw8IhrmmZBf1qU+HPAGFI0L6zmmmDryBsm1uACK0aBpce/LRn+WTFSwB1YX1G7MOP8kEgRVt3xRZmDI4BGBG5eiiQk6vknhevFI8ifnXZrZgObB5bXSChddmtl/dZMtgRaxW/eExaVTxnl6y/cPhF4ZbjkQA+FY7R3JI4reHOHA8ZN3Br8UK7qo0m8Occts3fg/ukU/dUuC6HFS7SuRzF2kOSx1r0aD/96+RXdiQUTyp/S76oO1PE1Ovjbe3aRTutbMC8UhbrN3SYZ12atKzfJRHgx6YpqQ375iYbwmLngvhOiW5HHeBOMzXdBNz0ZRLjKCQEIb0zZAYoP7rXxZWW3/F3kbSg5LZ3QgZ2yZt4GRX2cw/P2nzThFA6VX09iSgp6PIn512a2YF4AuWzAvCfLw7JncV7F+K6s8HuYwuBjI9h0AmTooAo7vj4azad1odk8Eq74MX3zYPdZAL584Cs7kI4p7mBVPbQoe8hadHDyS6/ruztHMvQP9fZphgWzt/Vf5TZwNyeu0geXiI0e2zjyq2QnMC8UjyJ+dWUY0JcR+ddz93DQ6YPErIicK8IY/7+jR1UWXPbsB7mRDDzl0N2sEoVkKjPQ0nyj9m5XybNiCXretFt41i8lRK7MPTpsmqMlBRrRlPFEI+yZUh5IFbBEX4wt5tHxbToRznn/v53+0evN0H512a2YFz95eOfuc62VQrg/tomA5w7IBnRtTpFWq0cze5pUvzS9LsFPmESWNUawo6zOL5tZwrRODZvCbNyksb+9LJZDYWZihKgHZIkvUcnCy4d3Xr7AbpY67nMdmU6Lu0wF2rzSrLXJxHXpLW4UChRN7mrEn+XP/2BeKR5E/OnqPIGIeBv6SzWopcens3vlsner4Nn4NVx5netcVKW6bq2XhyHOSZmmbff7MLVZ9204ElJiBL0ZF7vZnF8jsLRNKco5JUZ+gHWxGerwI2wL1qT22KSOSxw4lVuJvbzzyEE2uHpC5qSIjufnXZrX9ly2Am86Uh56ltIMDWE0PIPXjfCkNA3xn7mI4kCt8qJODD0FRr3pp/GA8Nh6V/UmYnLZf7h4u58kojW0lt7xdjQ1QVYSxvsKHDnT6tLknjVGtT32jK5jU5Zr6N6HMqY2+g0inda1oWOh8oGGpKJXN9PKT3nIIkzxWD1mjoHqSoaYZjxpUu0l4a3orKKi2rgNrYO8llpWChMDGHt3rOLWgHn+3GS9mbvd773nEZ/H9hduDC5ijAyxvl/FM9x/jADRsIWPJtvWKHf03IfwCceQ6W4MmeNzDduOY7lKctpm6Ri+34k0J+ddmtl3LSY/dSYA0hJZOqVYLJ7bBlzniKFjnLXUcJ2QSvQWIMjKh+MnDMi9xPzwX2v+bzwYSFcoSVVG6d0clhx5RgO7cvr12D7NSZsDlxmESMxAJiAA4AnlqyY8+jBLla9sGZAwie9VJ9ydei3RzfNLMGq9hcadn8M2TP4nDyM51MS3dFTk67NbMC8TsZo7CfFhpZiS2IGoEuAF8FNYXVInL2Bdos9tBc+4SAnKsTzrq9uJDOAtm2S3ufhKu/kjaE81mXcc5KIhnT1OZxc+TEwVeNCESOxea4OxMAiVr1bdbr5B7q9y7QsL4N9y6FAEVhga/27MSdW0w8dFfTSBfoNIp3KpvE0wsztJgUWTxZB52TTNCqDsp7YDa8dsqvB07KHOy2guTnRv57HK4w/tMkkeYmT491NjE4nhF8xzoR5TkesjFiwfLYZ3dKNJoKCEYpXhucMbZQOPfuGMZK/DtCeeG8UsQk17kFrdWyT4rzn512a2YAUbh80ME92vwnlsNZya1NPnG54PeUMR8lpnNMdfWDU8/HJId0Rccx0Ymu53CfoG160HpSraIBhMd54omrES81G3t0Jws8qoTaXwHE4TNL5qoXqYK/OW5B76P6DAgcUWwh+NYbNJcO/Q0xH1X7ibHwhGOZUdUvKfnXZrZgWmneFwA0N+XKMcZ7zMr0TVA6CoZu0MONhRFZu9nSS4F5NgQlNnAzb6VLoURkJ2eiWPGm5rYsn2Q9tOLs6Rjw/oj2+NJZ4cbMD5VlUd86BwK41omcGL8c8uxknNmFFfFhf3xiTraG1swLxSPHjIRTE/qgrRi98VcWnc8//AqxdSUpPw65nEV80d/iQal4mUKO45lHdb9WlQQOtPJxe8zszKUElnxxBSELxms9oqacRDWhJ7qe9sPgNm4W6ZgWaVMSBbhke0bfS+OC3h1xlLHXwkFpbqDHc/OuzWtCy452BRTUJ8AJmbxKdjFEBaUVkXC5ry8syKMgLB3lsUOTmPTUwlpic5NTTpgLhVMRwfzXHwv5V2uJEjPWSU67XhZ8nBXK8fjHZc4G9rCz4UOsQlmxa+pFKhJzXX67VOgvDBG1XM+MolwFRN7nFv777fJgdUeaayRD867NbLBXOj3iilhvaKD0syii5rJ3pzMNBxrKE6OE8MmbpbV+LSdbGuVFedYSO1W0gvv1Uj6oQHxM9X2aPVwUJdH5fLKVFFiU145J3xY/vHQd/U2jhlpl85EitZM7p7F8nQ5DmHeYqyxOVzug6WfWX0SjPm4XuG+nrsDSBfoNIpmvlkoVEysmL9ftMNARn0KrEj6obtvhOu1O4kigdX9+hcvFRSoU4WwM6YMvN1Nl2WVQkZD/cOUOXFGiAoVj+JZ5R0I1FnDOJafndD02YCU7SjKK6gzuzn+30k9+N0NxrQDfwuMG7qnZuhuf10LVbqPFfgXox27TMLXyQUOzpsXhKMm8vpcUdz8wZpVRo8LPXbN4VL1bq93TVWyGJrHd3EefrygzXvHYTlN5XNvZIqT7/blbthCsHAL/7Ol/CC+syp8cRkJkChiT2+3lgkSLWDXmopBF+/G/e7n48GF7Hkk5Z2ENjOZJX3GrgyS/fMjtVRybDUPeGdDeIIibeKCyz/j52kjpCfnT1Hk/QXu2WAKWcwKNoIYveUtwAYDU2wc2FqG5TMaZqVdcFIhfGqiOnoJAAutZUpnaK+lMk1MSKFBl9UWpUw1RoG6yrBXQh8bOad4hwjxcl52DEZ9JFDTFRKm6wqCdojSLx4RtssRCftnb8p5deObfVgFjYVJCBXpQ4i/2Y9Ft5+0ZqGo6lQqMURTobZTUbKXLsjwI9x/XW0rRA2FQkosEkti2sSndG10aNrtyFdIfY+8vGwOESkWju998nCIGfPkX05WrpM7j9BES/ecmuwxbCt8WNXR/LAjBQEcA4S0z5iFpdIMywonnkHjap7mCfXOHVNEpDV5CPWDmw+14qPxXdxtkr27O3Vm1SOa49tPmbuqYDiNJ5QP5/zQoQETsXleinpAvxDHDoFClyfTey593LKnvL+JNgxlZZmAfEJRzq+Bw5CVg7IaBd/NNJdzmBDYJgBgcURJvDIdKGpvgZoWB2tuAdEhOszxrdHYehbkz6cDGbJcKIK584fRycdM/wSTbbGBGJh7IzRry9aOAR8Hd9w5pfqJQnR4a+v8rwfva7USndaPylqA8wu2oTaHzyR3MR2XvhhFEJKp6uONv05oO64+/WBtH3dlVPK/hW3n3WitTVSKaToKwvQKQ6O0DKyIudQvhejaklhEXat48ILdXArVjvr0y5zO4j1GTLUjlZOFPI+j77ph4ow5bstogkkG50bWiNsxjQ+6nBoNKst75IkgLEBiooM1T1d3xZalTWrkBzmrnMqv612EnMgZKW13er6s/WStrCvYJM4bbGCmbx24wj1IUm+1sZBatoobsOKrfhC3Wg6CL2es7+Osd5Pcy2lIlPBHDDToUOQtXEtJ86d5hA1cF/HmLfOClshhYBq+JsM0it12UU1U8P+qyjAMjAGvmGZILXTolqfLpL2Sc6G4ALtbQ/+lRQtnDLwXKPycvc3kY7PFghDhPJantuoRhsZBEaDQi0KbccjNYYNYHxmqarXMte3YWaM/XCtBHgPgZ59w29lOXXo4H4p4BvJjeiDfc+gybov7iD4ZmVVB7JVOfEECh9MI8hjOt61GZl5t9ODyEcVRuEzKyrm5gYe+AqwDNjfh7P33sAGWBMhz7fZkwJiZgUCUN8/jtdRiAbthPqdypa/vnr6CGbhUQDMWGkCbZx/84gh12AU/5N5+IhTSI5P/hxWqaDjXaedAfvtyHF7KMsmjjjtggaK9yVt3ntzKi2rATQ+KnCZOBc6DaSQlgtJFd5IRDbMyRGg7NxuVOigWUFNFcxXViz/LO2jbq2N5+42yC7cSm4i/BAUBDOMToSMkzWqzqCftVTf9bxaL0ARKWLPCxjIHckPLsNbWQ5oYTlYzbl39k11zAYv5d/De/VEss3Fqr95WkzXGMkegEj8CZpNX9LC/gEZAwtLaOvHDywhsly2dGU5TlbAcmgYEt7B1rUAVl1iSD1pgnMUfzXZxX8SQmKo/wEwBFUrSn1ukFocNkqLhKDyEzsnDpW2dRTa2lJbf1hFBPeej35YqmjOjNUhaWEIPPpcaWRZaF+25EouWZiT38SVfGtAGWOLUTi45FVNN+oHOqJS4a8sn2o9rZuPDM+Dm0rM0WtDHPCmRM1/12uplAc/eP9xdW4mHU0Z27TKNOE4KiMAxMkb9ofLrh53RFnKRcsnhmfy+me7nFSa2nCig4ejejcXDrU5/l2mPPeMR+9U5xDVtmZeAzcW4TOMSA9JNeFqDdZ6Vp3FwCkXutqajc51Xoch89JECC6+4+3Fqz611L0Kiyblhirc6tZrGCteq9rMLLomKH9nXDNcKBSsSRwHtUh5Nas/fetSusHNM1sRI/RD3NghJz1+y5yKesTHFNmyMVgbphtW2iMM2CcOgtql4ucaOf9/BH9wGeedZdtJtnZ1ElpWFTvaqxfu+YMSCY4GRzgY2dVeGkjvo7WcKsiNBuJk1kHLm4lz2lld6F8FEBUhvjgKSC4dj5H3oXkleEcTfh9RUKUDSiQULESuFubcYvmkXLTx4sQUUFxQg2P35xD9eHju80ryZyn8R5Ry1m1nX220pGWCliurCnFiS7CDEF1avr3Vc3eQeN3mLjL43K8IOmUk74uLP5C4cTLx8M1D39I4SKI8HN0cRRGMJpcuMLaaNuHXKiAgjHNGEKolVIJF72uNzo8+s2f8j4atTgd7xC152qHnjW+cBLkvuQl7J6E2YNeUWbUO3FBaJ6m2w6BC0kGQH4pxGXbeg7/tK2o3Ys+corUySytjzuDuVTb+I1ZMGNj9LA+QnIp80CVxB7oFp0EGPQsuYmFz+uzXTylpqmSv8anSAPt2OCAoLLwm2QvmaGSEFLo8NHAxUpRd62vqFuDuLIt0Wnv4cbGN10H4h5G0AiNeWGzXSLEqDR0d9TddB0IXtub4izmHXuD9MEIQcZkN9/wOgMJTfmhsSf5MWjaJU9FZmunt5GAiY79ikm/QpdH9BXcKGFtd2VYJem/S8dOgDD/GTUhDOhKQYkqHMUjUKKiIM5V07NaaEL7T9CudcUr45wctaAcNHx8+hrZdT+tP9Z+yi+XCbvniJJ4JQp0UrQUnhJpwGnVXmBRPrp7y9BC0pHhvUlftsN3iXhUVzn8GSmOBJELshC6P3PTBgs/pB0MV2RFtFjqVyVRAINRyHiuVF0peVSlvW3G+cH5cP3dBcC/M3U8XFdxzKVxNot5UZMqfwJXiK9H+kEbu3tvunBP+w/Ib4dI/uuWJ+vcJtPXUnZ/NJ/553SM51Z3FIbEQV89AKsMT0+IiAIvvukoKTcBZiTdr7N7cDr1jPlUmh4lDjz5gkgVckdIDWPyQiDK/7A3x70k3l/Q/uAZ63s3TFKv/RAmTVotpFvwhULyLybzrr9RrY8X3mkHQa04BKuFh5RrKqDVDMHsjM3hVnYlycq7jepn7tr10dd4SNIE7/E78K7oa8Nn1HHhEKyEJqWUIV4+Tz6HRZT2vgPLAAhYnT9VcM3AFDCVW9MIxwUP33WzneHITkM2GiNG2n9W38zmnJIyHCVSz2/sF2QtLnJFL4mHUS0ULAaw4lmSKK/5McQ+O91/rHixaYZg5Xr5FgEJR28cg9EaBLt7ZQJKPZ7ZRbRjAcO2vmm4UxF7wkac+X0+EUYslfs+0K/3RVoLu7Z0f7+P7Gtei1H8Pdeh0NLKsDP5TrZYhN1AL3Kz+cGGkPsbnFH7mCn8ebTcoElnKD7jFoZelySo0egfzLBocTKWDsgfXfGfM+mhP9JXwyCKkfjSeEYYH9T4pjApK/JxvSnw6hJbBYIrFYMthoB5H2xU9p+3TimAD+97P/9vaxxf9+EUrWghTPTVpwAADIUXLVn9tNR93jpQ4Gsu6Eu+BUdYGSXWvj2DA/x6aXQHtWrwjll32wFk7YBwjj1CymLMFOaA5tq9Sp7V67LmZcCA/oGW9HOg+JdHRpyj39KqSim8z655vtiTH7dyuD91JWX12148DBi77W/sjDyrCNRIMcfk/Od280EhADux+Y6xrOLsgAAAHoi3UjX6r9cO2+VAWfWLSkLcRla3IkrXetZAAAAWuqO7e9qiui4Z0z6IU27HPGnb8Ps07ZzysUuxughBWGZXg0XCYL9XBCn0XULKbrdV/wQ0SxqBOHMN856bVXWTgyR1xAzYzczmqJCCm5yGqUtG4RS26pxsiqRAGYfeWll5fJW1igEgflcxfF66BqRsxnPsfa/aMjKZn7gbpRtjwVzekcC4CyRvQn0Vex42+tUy7OjeDKsI+YgAAALNRITAADXyLLClfVnZsaoq+J80Z6Koahe4DL8SZqzGni2ZyiaXyaloymIDBOO2HsFjzS4i/gDe+xqFKqb+h5ecG76ddvMSXipeinctTxlWLYXZr6yRyJjz51wzPKT+jVFFnsyeCi1oK+U+V2o0zPTAi4RAKMyzaZLfsGfazFHBXh7Vjuy3ahClmMsujQnMpqnLJax2JrBCdCQ//Wu3AAAAgC+0NAIGUjP+JgBYts3oPc8f1gWDl/L+B2kaSruKgUth5iQd9NkU5aghZUnJvtcwCN3X1yCu5XJHvJXvehGy+eRrXsQtMdG/HsY08AFOFSN6gO2zA74vTtp3y/brsxbn+WyDZKr+7hKPctpkHefN2aER/ikltCdyJJYbeStC/+0Yo12LfjKbeSiMg2wbhZf5znOjDqo+S4u0sIED7KwCX6QAAAADpv2pOAAoBWHqrV7uCBL4ahh7Ik37KWJZc4C6EgR4qDT/XKSxBponXjvu5v/5lo4cwvUKgLtg9bz/5EH7ZeaHp30H65tYaAYO3nrqqsxIjUYC4c2u6bfmoxtU5Lfx/06/hLk13TZVuB5TPskmPDlsH+yrxvwtjmcLfbdrJmbuyRAT8gkwDXxCtE7eAUsTS0+UwPZnjMOs2MKMHtYKVeRCe6IJis1mz8X87OZ3qYAd0gAAAUajw0n7GHnA3kCJu5aKGo76wgfTxN/E9153Kl2hUtC/rK843I7p4jMDDkGkgHNaKbgAqA6+h2D5LeWIeLm5TVipl07Yrl+IiUVfh4pwI9kFCW++W/ey/U4pln3ba5o6Nnd5wMRSbVspTBOptiginG/e1YQa3eJATs9FqqpgWYeDrIlaTn/lEUlgLY4vKCN3J/GIMV3CACFUMo+mXn/qdSlshmZ5DM/ScXEwwxPxPZjaBe5mCRh97vba2VVCuH4iGaUSHtpx1IAAAAACooCL6xNZpHrPjXS1ap0BQ495FcWimslQkk4zzNmWQ5b1rp2+T1ws/JcYNHKaJ83LMD3dAKEKReNbkzbG1u567tF3dbiErriYExgiIuDZixi1sryg4lCYfLHzLkLkCnE7ob4v6Zvm4F3XKFuy/GYqplRNCIEPwkL7gV82B7hk6sDAcYJ1MRPZLYRIrgVYn/zPTQAqgdyKXqTTU+ZAOAfOsI4NER9i4bVSdkhzwThjIPXlouol542pU36QAAR6rvmAMMan13ct/SsCRaEJ19wdPnkNSCpii85qFLIRvTJBByi0KHs47a0yLJ0ZNH13TKch7s2F6NXTQiJEgJIqTrIJ46rE6A3LV6Tl5dNSPccfH84QlRn3eLDASY52GBAxFOVuq7CE9BtPkpSFF4fKa5TRETg7vhNKIllAoA6+ohbn8xstBw/TEdZVwIAGjmAw3uR9e153YicHwwRoPunVcBd15QlaWBf8uuiG43lsePQz5GHgDSgAAAHeP38dcH3fFAATCnR7jLUUR8n0JK4mIxy+ts4aeuJ4c97wZ5pQy+eXHnXnOOQAtmKTqVjpdIFHaw8o7DYjZSippFS2Xq8EEhH0eRGYT0WVPow08eVQaYgNM2HCdJEtN1bc+LzAdMAQC6j6BwcJZl8pAOhE+Wfg9/pLZWzHMiGQ9aYN9J780Jv+2uoKPjz7565cO+0ZiCo6WCrZEXSm5Rd4ktmNtHYGQf2ZMYtx5JmbttPPu8P4ECxzA4X99ljWeX26Bq3vAepTVuAAAXRazD+3A4PkG0n3a3zSgtelxis/I052haLr5dW26uyPq6cT0SgRMG06Jm0bb7ujPEoIG+3KwwkmMFeZSCe99EtSt3JfNHWZ4HSYduYGX0NiV1TbVhUjIVJYqyuQ9Fh2nFwCK9Rq3VXf7NyTwm6cUzG5SuUewLiEELKQJsnyl8waaxAMFbECykpOQb19F6uUNZKbxlkYzEBeneosIFjp/PErtEnI1ba6dmP1Mcw12tJ1aE/jpGZ8ddV3C6xOl3CUqahnB36hQ9BY/D2lKi57GfSAAA3J3UmGwiPRuoqcem1KGMKymsHj3iWkzjmEdXQSWfuduLq44R2xjeZAlBId9df/ST/YbBpEZ34+lElcJvYFjQJdZb/dmktJAk8kRtJN2O1iI78/mkiua8qpE3bktZLPbyUoPSfTDKfRZrGZz6zJba7i/vL/XlRZ7qBbxTdQvRA69ZR4XTS7sUZHKUpp6HZePzSb9x3XdU/6gmI8qzycj8TvHcC5XV6Z454p4YI/+c6flmYXmjlPBSd3sv20djVLkAUNXvl13UxCZsPZA0xn8+83hUtqfs46W7nX1a2kAAFYAChNedz7sGXs7vXvsKBNtJKrsxVyB2tKDSJPzjdCPBv4OVqjfWW715yXhKg5K44LhuaeDfpQs6xxBaE9ZBjTdnmy1C8Pwl0hx295U39xqXetk+MikMqKuqnCLXMupGbxfInza6f3x+DzqpMfDsxlRWw2Tbww8xD2MvtCD+Yno1NVns0R+31NabkmKG2EV0jf/uR+8RxLFXfcRb4ifJpdfq2vVVfLBLIsfl80uE8OZx/fNimcTpzkZTdyp5N+RNUd8BtLcTjj9xLMTXBVyY82Y4T3bM/q0aB8w/VU4jrgAACGEMT+XPVjfr991yjJuXf7E1Ru+AGCjhxkafW4xB+b2yhO6umzw3k0lpujVpOzHTj3G57XYqa9haeJj7VgPa6Xzp31vfEc437fP6YPqhC6IReI0NqbCkr2pTlaWqoIu/FJDg2lTk82X6NHE+r06ObHOM4jLr6lTFdTRCSNO7/NLMgpJUH1SMd3I2zPWQsl0WvBfS7tX/kDuIJyB9pClPoZ7+IOWfeL1jrraZEldw5VjylSAAHouW5stN/mMwWYjF+GqE/OWQAfAS9wMQ7Cwhrf2mnOfDxUP6pnBEdPDViWxFaJnbt/cmRv7PqZ3R5xXgnRAndQ+fOTotkMZdOFVy2fKjWb4gewo5ncRGNAiO20cCR0xNWSIzpvZfNUBubFLmKgQTOyYw1A12thqvNM+UV+c6AK3Zafmwuh4yyT7Wn1LeXpuuRsEwXmNltsl+xHVC1nULLU+hqdxU3+4hjdWq/86PIylzbIaqhnmAoaKiQAAf5j34TXBOmQHTrgNASks2d/XRjmyMnFbsxgTpfNqDv6mG2Io9g6BEWekfV2OYX2Ve/tnrKDgsALtnpv6oEoxETigBb6XWHUC6nCk9lIReZg62Cj7vFytxvToxalOiPbD9hO1l/rO5tUsMdUx1Tj7aLi4vZAWGdH40/o20dFLFR6othtkVgViji/lA39cTg94p8qS3TIU8KWJRp3COm6ZwueMXskF1MQYIKfhYwBv42WZegAH8UTLDeEhZo37ypMkJ9AgsQ1REB2F30I/fW4HqRxquEzrxs1ZidMKQiFXlXzI+F11j/JmswoUjqdpDdttkvyCtE8zcyuyAcEuHOkzDjbTwUsXZuCr2hRlitrslzHqzE5kPRPWmU1rl6BGrBvmMTAyRCu0QKOd6+9YfrooNmUxLq4I3Xx1ndWrd6RifThrJh6/Z5SOZ63Y/qV0OP3L/EjK4HhQ8n4k3G1dmXvPAEHt0485Cmz96jjHl7VQ3/lU5FMWKcZGKcXFzx0H8XAwvFcMVnigWY7RqGwAJlbMKf9YRLRMIfAOqMJKv91yMQzvg4P08QRSOJX9IGMoUwNYBEXLk5L+iW7bYmwG/vDztuUyOUa8FCIl5O/na6SS6gz2GGHkRp2TqB546lun0oWdo/OadtUQIVVxOJskv4wpATUF7WId/u6D5KVoElY7ilXkY5tBGqnIGmfIVu4XDX9xASZh5vJKu2pB43TmRTm26sQLy/rHnedqs/gNY29Y/T5/qVX19Q2c7UoHl08e9M2MFddpv0uCmd3/Lrf1weJavbFX4BqKaMvotIwDFFf+nwwrZpxt17NFvt9W9TBAAQOok9YZCqn2vuBNpXIrsC4w4GFa/RiZONUbObNp+E71rKsulLKlDB7BrFllzIBvBuQCO8RTFpv0hgBH7cNN6IohutnpNNxGoA5vUMpiGmLFBMtDjZkvMqDvujRADpvAjr9cscNEX8olQvyVCshxjCaVQLAz7+H7nU7C5ncHe+s2fPtCVQ4cZPLZ91/g6TwT4QCObkzjnNKvPej/vo08o8W+BTKK6FCxX9ov/ve9ZLg8R1ANnzXkDZOZTAZhQAHUAjM9IlmRtN0qzRF2U+CaEQUnov4Kp4ffQOIhS7horPrZnp6ppy6JkFZ+u/9rP6W7U+uQuge5RJCrrxDYe4/3HBy6pRC+1ccr8fiMXupocO51p/mGkYHTrqc6DMClQL4RIk0u6FXzmPJApVURBs4gw/ozWd7Td8kzB1ow6JKycBjEe3Tbyyni5+aohnH61taGWv7i6xSPSBbMlc3u5rQ5TJid48BGNCEtC9ezcz4lCvPcBm+/NqR4J/KYs1DTKHqd0DF7lqKOF16e6nUCUl99i//Hi/qAHWgIeuWXujTHjKpClQBwbiOB7f4V0rWTGvYjc/ZstVTswjmr246hY3BerFQldwULNyO33pPYnkboka7dka1nUKCzQT3HPG0WOSxeXQz5nYwwFsD0G37jC8qrhYYnvrU/s0GfaOYz98qgSmJVm9DOmuxlKRjzkoIEEm2CxvS5MECqKn+kTxsHUIb2C2u/ejIHb2P8bGcZlZ/O/YAl7hb/4pnTVh1DJNRngprVaqhI/bSLGg26rEXnvG7MNnE5LFiSYz1RrgglklwO7O5KpNPegzWwAAEwM5XRI/FWABkvoz7ZqZ5Jz2AxLysPUNPTbslNkAUg3skqPMTAu00SoOU61ee388gsXzt62dRoJdjV5RfRERYHoNVb9EmajyH4Wf4dsmh9GbmzPP9G0pU32V71LpxYY6EnmzGgsWUWFbeOYO9DW37Onz8PZ1mo0MewA9zWoaGemqZJzvvn3q5A0kn70NW73/0LN0sGO0pslrfzGwe2KalgXeP3yBEysxGl/PcsyEtyogzJBbGgXHSKs6mIJUTO27DQGbqcdG1nxEy1tsr1gwGLnPCUokSGqMu1Qv1Qc0iAhn9UVUbclkIdF5JgA6mP8HsrnCVzuXRhnlE5xM2NQdYwGct1ca2QQJDcmgTYaRKyjpLphFQ5QOOLByde1V2q08KUWzOLcCqkfB0VD2mvctdjpDzhba3lynhkjqPBCVA9AhaADLG9FgbkcnrDeQNu8UeXuPmXggrA0Nk64MEiwPr7yu7FRt/w4B61+HmiYgUiyXR1YQPIdTxPGVNhaU1ssawPTPUzccZl7xb69BHmPn7iiGBeoFIWtuq9wStxuXxkh4QvPPXBGhpeczGjU0cGuI/qp/LvUzDG2lYB9OkbkJ4EO0TiQbeIXHe7WMvMk+/84F708hJ6hUGBal5qFTV2AcisAAGcVDjSs0l/yT26n18RPE2n0EzSaH4u9ll0OGcmaVT3nIHpbNry4blOkMpaYiDyj+rBO30fU2oMvZCAy3mBJ2RNpCfLS5ui5XnJUVpAwkHsZtWkBpYmD0dQu8ZVtoSXnUImJt3EfvoX5s9JRzoeY+FD4nWIkG1AVxYac2qNM/qZwUG4NHe56dCaPbRQusZOOIOXuiua81yN5e4tG9tz+6A62ykWzNwG+mpTRgiMAH+4JhQ8RTWR2rdaVqjCv9uv73KI40D11mCbnfAGwqgRJD6rGbo8ZVV5ngDdsCbEV0FaSr2SalYPbrAZXpmlors5iU/owjJMWZTooXlFbRYd5WFqNAU9ujxM/NAzjKn6MIu0yEiJcWqV/6ZMaUM2LcuulWgQAKvNFYZsHKdRnWIoyx3J66gjv1H5gI1sbloZUVeG34x/JwZkyXC6ZBCt3PYVrb+blOoMx5Ivo6sHtGXYHQfG5nLbIXcr21DyELQX2kxM9pIT/AeslRNU+sEZGWa3u0RO5N1R6Z27mit9VDfT81iRDkWRVnSeV7jj55hmCWV7g4n+dz5JWFHWlfA4KvRO84wvHjF/aokTZ9Pm9XnCeNfwcAchiWMF4v4ZPkENyfspQGen8grmUTinxdSfsT0/l8S66F1Aok9W1pa82XlTEJxT0uToCjBq2BuR1I+YKDf0BBs67NeF4WUctl0o/xwj7moR0QFEquA3FwWadXPagqWlkjKdX1o0aCcLDl4WiUzfyX4dWN/kEL0JxBheXtBmNFthAtOQ3O6v1nPPvHseeJxcpnGz9omx8S/iLkq51ZTt1sVorasTJlEZd+LRnxxeAaozwiI8EwEf26dKPhzt4SELblzdHMChosVK7P2PSGJ/Ys+EtQpukwOrDNj9467sT1Ljy3SRkkwNHTBW4fVIsB/OsZhVm0qStr9sDi0DflXkJ+AvW5lqQUHp1Z2wZiZGIRpIkwykeRyTdJfXR9e5xYKDeWdzW3P6C0QSEHsVoVeLxQUoGeCGjE+8+cUrkpb2Q1yENbI5BAHWKTWG3WbahViFGyCx6TGJn70VIUxb6cyKgRIhTkdsXiONJWedWJFkcLGmEDtmg+tnXpeySGQgf6CjgsGyxF6G72bgoHwNOQ8suD/Jijqy2gNa6Xex1Vu6dxAtrW1pDZX/M71/OtSHnNElLm7Y5agIo+byF27Vx8q6AQE3I8eh5U4OisQJW5V3SaGV9GUdkIpgP0qFZTBpN0JS3Vr/pouOYeY+bcdc4lYwpqD7wLD0ZUCri2myH99xZCUQtZtlUMDpTWSw9+njEIG48MMDFosK10KAfHB0+BjKIHrItnDqD2hUypq7a1raIRchrtS5ZnmwrcFRTqeP/pwC5jCTCcRxZSIbMBEeFMg0b3xaHp9uUFq2ujhRrtcyBTK1Tg/DZorM+uYU6N6YD+bTLxdyQC9sO9PQtxAApA5BgDz8rx0u/Z8ILZ/9KTpe4DKsJ48lLctu6lvTXpbJpqJHevL5cafZlBresW0/4uQKIXP4R7evooHR3O1ayy9C1dIGcD651iIb5z7u1HYM0o6C9O7GhG04i9oHq5uTlDT2eNEa1PZGebthqKQcautHL/xNXbV0BKZopIqaSaieYn+1AxffgFDHXmpkjNK3Jvd31skCOdGBk58Hw7TpGXgWBHVFBWr4LDuu96sP3shRPeO2Ppdr4eNBcE1wHcv+HteHgYBlbvFWvTr3GBU5JzEb71cfn5Fz+mSZ1gdr3wK/k2lZYQCkXw1a9hPkpk45or0j2phFqWc0KTiDycVL8X5NjYEW7Xcqlgr7dNjoZQpGlOldCVkrNxgPNkDpBs6+f1zfUN783e62DyT/gAeTY1V5F3KVjvr5U+bmtjpVcHkjWBTojG+Qulf8wMY8CTxOvdEo8NzrbRkO1Gg24nq1iCS0PHTq4CAHUAuk3NiGVcaHfJQqiGhqht9lH002tEFuYRELw2xsEiOgJVu4ISR5MKWnyYixFDD603G1yHHzTXsjKcsBrETBiNY4tKYDtrFQROz+UQ504wNsb+AN2Z6cwVkNl0bSQoo7A3rUdrrLT9MmSqlehGyQdSJd9lxyHMbQmoJwrXXwSZYLJ87a0m0bmSL3BrBUxP5ur9CXzaAenwOiF3HXBtWWkFvAwegVpzd3IdxfTi7Dmkn4RCvTVqgbY0mCIS/ohhBHcga1lSwYE6ra+dbbscPwXBzUucpCjrBEny3IRf+sPCR4TpmdINradf9My3bujxqpu0v2vbFSGWUDMKVDCvoUjzwWMKUQeMp64TEmc4hjLfI/tmfr7KemwOajrGiP61w3mxBS/jRvcDKIEgkGnwHHhLXiUCvqMBAspzfnCST4BuhNmnJ3+YPj4K2ON+YMEuSzzlCK3PY250OnH6NuNwgEh7ZP5LLRAu8MZbjALNVxshPK4RxlLK+W9FkwhhEY3LtuGG9WLt0P3QlxBUr0fXfZmVzeZolrhn8uK1HsGEHUZwQ0VX9abmxR4aSYpYEaI9xgR/NrGsQ6njCSKu4K5E5dVV8sc0Jg1gzBvCjLmjN0L2a1cQ4y3NaM4pb81KVZbWAc7o45qNzNkLEdOrllP3kfy1AvcZX1QZnYdhiPTR7hbKYUL+M5yBmKUWaIVfv7npLqKUO10RyEPd6OQ/rVMoXzAQIooBeybnUkF74PdDM0p6oxAtwnZFDH939ExJCwLupdEjj3AyspHFdbb5X0zDLR+TLyyUDvedhDnrfOiR8hKREHQBHK0w+ZV8OZw/QmNAFau2Zgbuep1cuX3M6KLDLuGFa0goFPXyEnWAuGKbuN+1dZxm9AsY4sQFyj/NMfDNmOz6pdR/YkevhiE0ysBaIW/QbuoQxqcAh6kDQnI1UfTlsRK7Vp2Pm7U0jBTRLDYKDV9cP4ocMrdHL0pMTodmFPcX8hPQR8DmRB//iJmS8/mbuPcBkOQX8CdOhtyqjQvADLZZKg1HkyWhVVAbWbysxrmeksSp5z9buULYYcyzcMdQd4u6WxdflWzeHs/td1LKEYmCgR5r7ePb4fCLSMIuU41bG7ClWrs5YU1uTnTVQXAc9WvzlqHsGxoKNLUcgRdoe+9Iz7dCvBiNrBymL0ay6/izwhdBJ6CIPZUHWq6eaWGwXuMFCT/Y/wsDWyrD8oqsV+1XlhDX8l2p4DQNEjVeK4s0aVKt4RMibr2EetC0N24lgwg5pCP+Syeyv3aq992/llwIDs6xCckcqodIpzXGUJ/dSPv+26ULm1ixIIxNi3SFJnDd/wTeY7KuSptJDiWlmO2+mkULhXLwb3ZGBLge+qjkk5xXWOjnIkUDqnz38n8CLiu2RRvJK+KUDTf8CXNgOubCOWbT64ANTSRosDIUvbZiQhhLqsEOAH/VogFGKzH2KOKpogzNZgJNJSUq1BKkn1pRGm1g4dfoeb60DV0zoQUNM+HxRJrY0/2jYy7l4urWtxr58yNZjnPBAUXyrsmbAyyhvz4KmXi+FDQI48fq4aWt3s1HkESLGPK2Q3iRmaODDIGb1mfZ59jvdeIbg2KKJrrMhedinNS88i/h29/xMM+xDGrIRQ3wUqIaQjtsbgCY3Ik4hKcuo9rpHQCD2GmQbnsh2jccg3Jb4GkKa3wAiDStj7qzAwhRHphyFIsMpi8IfsAY0dLp1mh7eY5NZXbFxMQgpDLiSQtHe9ZKNRQcv+m1+iM6zrRJBw5uO1okBmSSvkqDyFF1C2svvs25suKzd5Wpq5zGspsjX8u1rqoGaXOcLsKxZWh64g2ZirGr9L6fEIs5G+jgyfgki192Fr/S3oadh9hVwIKyjqAOv2MwnMh1Og6eErHKrQm5N1++uMnSwdeIElbvtyvVzKCiP8M4WurB4r7gj1Nh4pl6X4fzG0fcooSmEeHm6e8Am4zReFqd9cuZ6H7rsIxNkz2hHjjE5aSkqA0n68ZuuXr49z/zUdmtAU6Aotvgvf654bB68yX9UqVTQiFtpxbgrwLaaASqvw+rOmSYbInGf8JacoEBYvaHv9XGASGTDYWUJ4PbigUSVGJ3ig1NuUqYhd2Iu9WwFaU932NppdOg6s5Ue6du7JfEGHfCcS9X0b+M8hxZcJfp5qsElZBdjZsrSACSF+CnXKqUM5I4i0tR4r3ngqgpbW2bq/hty2hQCptwDZN1/ICxR+4y0k2BHw2D/mvorUfmKvjgrvn1ISbg94VUNKTTatlYFwXR45SG8PTfd8O9cR21ywL5cqGcg4qM58f3HXIUXnt4u7ijDiTOsLr6MwuKAU1HBsB17XUU/M0u5Q1WIIKXIrcdV5qu+2ORMyiq8HwsjWtsQNO5WhzBzPEIxC+13VJ1fZvYYOY0KV1tsveGnRuxR32vQp5KB05tU8GTk0DoHSRwDrRBNg7w5WhPvTOdSTnr2K4gpGOS3thiQ+GCm+YDBsMZJqtp6l4T1h3TAORalJOb9GvDXsbwDWRaTbMs6nhkgNosnKB6Pr+musK1cWvRWUomWGN309WTuNIu9AZZjL/YzexiiWDKrn9eeCZ01NWeKdrRdqWvJ2D/zCyZ17GSX/XR5U+2cse2qsQ/+UIRt1RWOXYhFpXV6uhz8HcxKty4TAS0uQrrD4MfeaQsSot/1bL8MXcbByHD0acF8Rrf2ZRjo7b+ulEW1ojohg14iwvF+0NqP3s0s4pVvoPbz3CcrErZATI1kS9j5hp5XY+7nQPhbH3PCoF14eJiwqaYj6VbEUyfUprZN0vzc8zGbZGT8DHP79+4xMh5U79HmdzrzAPtfNxLJmu8f0PeA74DKDvEmge7OboYZsaerF9CuXrR/XhHR2vXhuwh4OzinmvEtb1IEcAzOOKnYJMS/fS/dzFpYDr+6ukzFMzQqESOD2keMV/hv2kTKa+apUL1pMHyzn8Wbi5T5A3QZLs9Wdsc/Uzm4iukLwb4Sac8AOhcsmH8Hfed4LUHEH0n2uA//1yTsAxnjF/Mojg530v3XQUP7BIDndTCDm+Yv088VQym/0QaY3oP9ZeXMK34zWTpKTYDb9zsa//Rj7K13wjKlv9WN7sFXtKUHedXu62qjBnGl657Jc0wKQlFqxw+6IUTSUGSFGxgJGquVOggvpaC7UFVJHkG3XXTXYejUYmaPMqLbBubZQAeLyfNIie3eQls5f8HMoCneuPFDBQaL4QZbRkbrqsU7ZnrJ0nLA/dO8ufW1vUar3GclSW2Pn43C6eJkI9bZsunrivBsyL02FEVCigaLVALsMGnkaZbIkqhk8DWIDL5WeFikx/hrolWesKx0hbHhy/5JPXT9hGct1oD8YDTQxOngymrv0EDvo6wNqi/R8oQxADPX1o+JAbU6sklJwGJn/58X/6AwrileBFgp0dAEYbj7dtLyNMO6A2Dl0pb2PDJRyG82pKJM9Ejdn1aOcSoMzkL6WPNTDu+uDDJV27tgxrFzE4dqnQsO7I1yGkVRLP6Lbn25E1cGLe247/K6dKB1D9ENSj+zZpAW8aygFs6sVdmQKPld3GtaA53OGejYpGC/EWMFD6h7l64NjeCZ0qH4yoSN8CFUaNLx8YH6lgDS4KHp87VEoSjjlXm9RYKcdKNZuu2WxVg28+eLQUo1FgUAdA/4sEDe59cC52gUNKAE2GSPwnoc9WWtAsa2f2/AZCnTjvNsGtUYHpFpU+AtoF8b3NNwHnR90+H1gjqey0oB7mkrddNnqBjrPYcC3p3QVVJH5RtxjvVdLxj6ulyLzeoMusArb4YAE3AABH4AH8qTACLGbIQZNA2l24uSUeFUATpPfBylBGh7oKXjA0CLDFAABMjwAAAA==",
      "mime": "image/webp"
    },
    "explanationHTML": "<div class=\"explanation\">The given scenario is suggestive of multiple myeloma and the pattern of polyneuropathy seen in this condition is sensorimotor type. Multiple myeloma-associated polyneuropathies occur in ~5% of patients with the commonly encountered type of multiple myeloma. Myeloma with osteosclerotic features, although representing only 3% of all myelomas, is associated with polyneuropathy in one-half of cases. Polyneuropathy generally does not reverse even with successful suppression of the myeloma.</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "C. The pattern is sensorimotor"
  },
  {
    "id": 1438,
    "text": "Q21. 1147 What is the most common pattern of peripheral neuropathy in patients with polyarteritis nodosa?",
    "options": [
      {
        "label": "A",
        "text": "Pure motor neuropathy ee ee ee ee ee Detailed Explanations 1148",
        "correct": false
      },
      {
        "label": "B",
        "text": "Pure sensory neuropathy",
        "correct": false
      },
      {
        "label": "C",
        "text": "Symmetric motor-sensory neuropathy",
        "correct": false
      },
      {
        "label": "D",
        "text": "Mononeuropathy multiplex ee ee ee ee ee re ee ee ee ee ee ee ee ee ee ee ee ee",
        "correct": true
      }
    ],
    "imageData": null,
    "explanationHTML": "<div class=\"explanation\">Most common pattern of peripheral neuropathy in polyarteritis nodosa (PAN) is mononeuritis multiplex (multifocal motor-sensory neuropathy). It is asymmetric, due to ischemic lesions of nerve trunks and roots. Some cases present as a distal, symmetric sensorimotor polyneuropathy. Smallto medium-sized arteries of the vasa nervorum, particularly the epineural vessels, are affected in PAN, resulting in a widespread ischemic neuropathy. Combination therapy with glucocorticoids and rituximab is increasingly recommended as the standard initial treatment, particularly for ANCA-associated vasculitis. 1155</div><div class=\"telegram-link\"><small><a href=\"http://t.me/Friendly_neighborhood_medico_bot\"> </a></small></div>",
    "subdeck": "77_Guillain-Barre Syndrome and Other Immune-mediat...",
    "deck_id": 1755954606347,
    "correctAnswer": "D. Mononeuropathy multiplex ee ee ee ee ee re ee ee ee ee ee ee ee ee ee ee ee ee"
  }
];
        let currentQuestion = 0;
        let answers = [];
        let correctCount = 0;
        let incorrectCount = 0;
        let answeredQuestions = new Set();
        let isTestMode = localStorage.getItem('testMode') === 'true' || false;

        console.log('Quiz loaded with', questions.length, 'questions');
        console.log('Test mode:', isTestMode);

        // Hide stats bar if test mode is enabled
        if (isTestMode) {
            document.addEventListener('DOMContentLoaded', () => {
                document.getElementById('stats-bar').style.display = 'none';
            });
        }

        // Auto-start quiz
        startQuiz();

        function startQuiz() {
            answers = new Array(questions.length).fill(null);
            correctCount = 0;
            incorrectCount = 0;
            answeredQuestions = new Set();
            currentQuestion = 0;
            showQuestion(0);
            updateStats();
        }

        function showQuestion(index) {
            currentQuestion = index;
            const question = questions[index];

            document.getElementById('question-number').textContent = `Question ${index + 1} of ${questions.length}`;
            document.getElementById('question-text').innerHTML = question.text;
            document.getElementById('question-status').textContent = answers[index] ? 'Question answered' : 'Click an option to answer';

            const imagesContainer = document.getElementById('question-images');
            imagesContainer.innerHTML = '';

            if (question.imageData) {
                const img = document.createElement('img');
                img.src = `data:${question.imageData.mime};base64,${question.imageData.data}`;
                img.className = 'medical-image';
                img.alt = 'Medical Question Image';
                imagesContainer.appendChild(img);
            }

            const optionsContainer = document.getElementById('options');
            optionsContainer.innerHTML = '';

            question.options.forEach(option => {
                const button = document.createElement('button');
                button.className = 'option-card w-full p-6 text-left bg-white rounded-xl shadow-lg';
                button.innerHTML = `<span class="font-bold text-blue-600 mr-4">${option.label}.</span>${option.text}`;

                if (!isTestMode && answers[index] !== null) {
                    button.disabled = true;
                    if (option.correct) {
                        button.classList.add('correct');
                    } else if (answers[index] === option.label) {
                        button.classList.add('incorrect');
                    }
                } else {
                    button.onclick = () => selectAnswer(option.label);
                }

                if (answers[index] === option.label) {
                    button.classList.add('selected');
                }

                optionsContainer.appendChild(button);
            });

            // Show feedback only in normal mode and if answered
            if (!isTestMode && answers[index] !== null) {
                showFeedback(index);
            } else {
                document.getElementById('feedback-section').classList.add('hidden');
            }

            document.getElementById('prev-btn').disabled = index === 0;

            if (answers[index] !== null) {
                if (index === questions.length - 1) {
                    document.getElementById('next-btn').classList.add('hidden');
                    document.getElementById('finish-btn').classList.remove('hidden');
                } else {
                    document.getElementById('next-btn').classList.remove('hidden');
                    document.getElementById('finish-btn').classList.add('hidden');
                }
            } else {
                document.getElementById('next-btn').classList.add('hidden');
                document.getElementById('finish-btn').classList.add('hidden');
            }

            const progress = ((index + 1) / questions.length) * 100;
            document.getElementById('progress-bar').style.width = `${progress}%`;
        }

        function selectAnswer(label) {
            const question = questions[currentQuestion];
            const correctOption = question.options.find(opt => opt.correct);
            const isCorrect = correctOption && label === correctOption.label;

            if (!answeredQuestions.has(currentQuestion)) {
                answeredQuestions.add(currentQuestion);
                if (isCorrect) {
                    correctCount++;
                } else {
                    incorrectCount++;
                }
            }

            answers[currentQuestion] = label;
            updateStats();
            
            showQuestion(currentQuestion);
        }

        function showFeedback(questionIndex) {
            const question = questions[questionIndex];
            const userAnswer = answers[questionIndex];
            const correctOption = question.options.find(opt => opt.correct);
            const userOption = question.options.find(opt => opt.label === userAnswer);
            const isCorrect = correctOption && userAnswer === correctOption.label;

            const feedbackSection = document.getElementById('feedback-section');
            const feedbackIcon = document.getElementById('feedback-icon');
            const feedbackMessage = document.getElementById('feedback-message');

            if (isCorrect) {
                feedbackSection.className = 'bg-green-50 border border-green-200 mb-8 p-6 rounded-2xl';
                feedbackIcon.textContent = '‚úÖ';
                feedbackMessage.textContent = 'Correct!';
                feedbackMessage.className = 'text-2xl font-bold mb-2 text-green-700';
            } else {
                feedbackSection.className = 'bg-red-50 border border-red-200 mb-8 p-6 rounded-2xl';
                feedbackIcon.textContent = '‚ùå';
                feedbackMessage.textContent = 'Incorrect';
                feedbackMessage.className = 'text-2xl font-bold mb-2 text-red-700';
            }

            document.getElementById('user-answer-display').innerHTML = `<span class="${isCorrect ? 'text-green-600' : 'text-red-600'}">${userAnswer}. ${userOption?.text || 'Unknown'}</span>`;
            document.getElementById('correct-answer-display').textContent = question.correctAnswer;

            const explanationSection = document.getElementById('explanation-section');
            if (question.explanationHTML && question.explanationHTML.trim()) {
                document.getElementById('explanation-content').innerHTML = question.explanationHTML;
                explanationSection.classList.remove('hidden');
            } else {
                explanationSection.classList.add('hidden');
            }

            feedbackSection.classList.remove('hidden');
        }

        function updateStats() {
            const totalAnswered = correctCount + incorrectCount;
            const accuracy = totalAnswered === 0 ? 0 : Math.round((correctCount / totalAnswered) * 100);

            document.getElementById('correct-stats').textContent = correctCount;
            document.getElementById('incorrect-stats').textContent = incorrectCount;
            document.getElementById('accuracy-stats').textContent = `${accuracy}%`;
            document.getElementById('progress-stats').textContent = `${totalAnswered}/${questions.length}`;
        }

        document.getElementById('prev-btn').onclick = () => {
            if (currentQuestion > 0) {
                showQuestion(currentQuestion - 1);
            }
        };
        
        document.getElementById('next-btn').onclick = () => {
            if (currentQuestion < questions.length - 1) {
                showQuestion(currentQuestion + 1);
            }
        };
        
        document.getElementById('finish-btn').onclick = showFinalResults;

        function showFinalResults() {
            if (isTestMode) {
                showTestModeResults();
            } else {
                showNormalModeResults();
            }
        }

        function showTestModeResults() {
            const accuracy = (correctCount + incorrectCount === 0) ? 0 : Math.round((correctCount / (correctCount + incorrectCount)) * 100);

            document.getElementById('quiz-section').classList.add('hidden');
            document.getElementById('test-results').classList.remove('hidden');

            document.getElementById('test-final-correct').textContent = correctCount;
            document.getElementById('test-final-incorrect').textContent = incorrectCount;
            document.getElementById('test-final-accuracy').textContent = `${accuracy}%`;

            let gradeIcon = 'üéØ';
            if (accuracy >= 90) {
                gradeIcon = 'üèÜ';
            } else if (accuracy >= 80) {
                gradeIcon = 'üéâ';
            } else if (accuracy >= 70) {
                gradeIcon = 'üëç';
            } else if (accuracy >= 60) {
                gradeIcon = 'üìö';
            } else {
                gradeIcon = 'üí™';
            }

            document.getElementById('test-grade-icon').textContent = gradeIcon;

            // Show detailed review
            const reviewContainer = document.getElementById('test-review-details');
            reviewContainer.innerHTML = '';

            questions.forEach((question, index) => {
                const userAnswer = answers[index];
                const correctOption = question.options.find(opt => opt.correct);
                const userOption = question.options.find(opt => opt.label === userAnswer);
                const isCorrect = correctOption && userAnswer === correctOption.label;

                const reviewCard = document.createElement('div');
                reviewCard.className = `border-l-4 p-4 bg-white rounded-lg shadow-sm ${isCorrect ? 'border-green-500' : 'border-red-500'}`;
                
                reviewCard.innerHTML = `
                    <div class="flex items-center justify-between mb-2">
                        <h4 class="font-bold text-gray-800">Question ${index + 1}</h4>
                        <span class="text-2xl">${isCorrect ? '‚úÖ' : '‚ùå'}</span>
                    </div>
                    <p class="text-gray-700 mb-3">${question.text}</p>
                    <div class="grid md:grid-cols-2 gap-4">
                        <div>
                            <strong class="text-gray-600">Your Answer:</strong><br>
                            <span class="${isCorrect ? 'text-green-600' : 'text-red-600'}">${userAnswer}. ${userOption?.text || 'Not answered'}</span>
                        </div>
                        <div>
                            <strong class="text-gray-600">Correct Answer:</strong><br>
                            <span class="text-green-600">${question.correctAnswer}</span>
                        </div>
                    </div>
                    ${question.explanationHTML ? `
                        <div class="mt-3 p-3 bg-blue-50 rounded-lg">
                            <strong class="text-blue-800">Explanation:</strong>
                            <div class="mt-2 explanation-content">${question.explanationHTML}</div>
                        </div>
                    ` : ''}
                `;
                
                reviewContainer.appendChild(reviewCard);
            });
        }

        function showNormalModeResults() {
            const accuracy = (correctCount + incorrectCount === 0) ? 0 : Math.round((correctCount / (correctCount + incorrectCount)) * 100);

            document.getElementById('quiz-section').classList.add('hidden');
            document.getElementById('final-results').classList.remove('hidden');

            document.getElementById('final-correct').textContent = correctCount;
            document.getElementById('final-incorrect').textContent = incorrectCount;
            document.getElementById('final-accuracy').textContent = `${accuracy}%`;

            let gradeIcon = 'üéØ';
            if (accuracy >= 90) {
                gradeIcon = 'üèÜ';
            } else if (accuracy >= 80) {
                gradeIcon = 'üéâ';
            } else if (accuracy >= 70) {
                gradeIcon = 'üëç';
            } else if (accuracy >= 60) {
                gradeIcon = 'üìö';
            } else {
                gradeIcon = 'üí™';
            }

            document.getElementById('final-grade-icon').textContent = gradeIcon;
        }
    </script>
</body>
</html>